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Introduction
Alcohol-associated liver disease (ALD) and non–alcohol-associated fatty liver/steatohepatitis (NAFL/
NASH) are major causes of  liver disease in the world (1). Indeed, mortality from ALD and NAFL/NASH 
is increasing compared with that resulting from viral hepatitis, owing to effective therapeutics and lifestyle 
changes (1). ALD and NAFL/NASH have similar pathological spectra, ranging from simple steatosis to 
hepatitis to cirrhosis and increased risk for hepatocellular carcinoma (1, 2). Progression of  liver disease 
involves complex crosstalk between parenchymal and nonparenchymal cells resident in the liver, as well as 
the recruitment of  immune cells to the liver in response to injury.
The intricate balance between cell death and prosurvival pathways is critical for regulating inflammation 
and hepatocellular injury during progression of  ALD or NAFL/NASH. Four major forms of  regulated cell 
Hepatocellular death contributes to progression of alcohol–associated (ALD-associated) and non–
alcohol-associated (NAFL/NASH) liver diseases. However, receptor-interaction protein kinase 3 
(RIP3), an intermediate in necroptotic cell death, contributes to injury in murine models of ALD but 
not NAFL/NASH. We show here that a differential role for mixed-lineage kinase domain–like protein 
(MLKL), the downstream effector of RIP3, in murine models of ALD versus NAFL/NASH and that 
RIP1-RIP3-MLKL can be used as biomarkers to distinguish alcohol-associated hepatitis (AH) from 
NASH. Phospho-MLKL was higher in livers of patients with NASH compared with AH or healthy 
controls (HCs). MLKL expression, phosphorylation, oligomerization, and translocation to plasma 
membrane were induced in WT mice fed diets high in fat, fructose, and cholesterol but not in response 
to Gao-binge (acute on chronic) ethanol exposure. Mlkl–/– mice were not protected from ethanol-
induced hepatocellular injury, which was associated with increased expression of chemokines and 
neutrophil recruitment. Circulating concentrations of RIP1 and RIP3, but not MLKL, distinguished 
patients with AH from HCs or patients with NASH. Taken together, these data indicate that MLKL is 
differentially activated in ALD/AH compared with NAFL/NASH in both murine models and patients. 
Furthermore, plasma RIP1 and RIP3 may be promising biomarkers for distinguishing AH and NASH.
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death are active in hepatocytes, including apoptosis, necroptosis, ferroptosis, and pyroptosis (3). Recent stud-
ies have focused on the role of  necroptosis in murine models of  ALD and NAFL/NASH. Necroptosis is a 
proinflammatory mode of  programmed cell death that is an alternative to apoptotic cell death. Necroptosis 
is morphologically similar to necrosis, with cell swelling and rupture, releasing potentially proinflammatory 
cellular contents. In contrast, apoptotic cells condense and cellular contents remain trapped in vesicular 
structures. Although apoptosis requires the activation of  caspases, necroptosis is driven by the activity of  
receptor-interaction protein kinase 1 and 3 (RIP1 and RIP3), resulting in the phosphorylation, oligomeriza-
tion, and translocation of  mixed-lineage kinase domain–like protein (MLKL) to the plasma membrane (PM) 
(4–7). Necroptosis is activated by death receptor activation and innate immune signals, including TNF-α, 
TLR3, and TLR4 ligands, as well as DNA-dependent activator of  IFN regulatory factors (DAI) (4–7).
Studies using Rip3–/– mice, RIP1 kinase dead mice, and RIP1 kinase inhibitors identified differential 
contributions of  RIP1 and RIP3 to the progression of  liver injury in multiple murine models of  liver diseas-
es (4–10). Rip3–/– mice are protected from chronic ethanol-induced liver injury (8, 11), as well as acetamin-
ophen-induced hepatotoxicity (12, 13), methionine-choline deficient (MCD) diet-induced NAFL/NASH 
(14), and concanavalin A-induced autoimmune hepatitis (15). However, work by our lab (16) and Gauth-
eron and colleagues (17, 18) found Rip3–/– mice were not protected from high-fat diet–induced liver injury. 
The differential contribution of  RIP3 is of  considerable interest, as it highlights specific pathophysiological 
mechanisms for liver diseases of  different etiologies (19).
Although the contribution of  Rip3 to different liver diseases has been studied, the role of  Mlkl in liver 
diseases has not been broadly investigated. Additionally, MLKL was found to be involved in the develop-
ment of  obesity-induced insulin sensitivity in liver, but had only a minor effect on hepatic inflammation 
(20). Recently, we reported that MLKL-deficient (Mlkl–/– ) mice were protected from liver injury in a diet 
high in fat, fructose, and cholesterol–induced (FFC-induced) (typical Western diet) model of  obesity (21). 
Importantly, MLKL was activated and oligomerized at the plasma membrane in liver independently of  
Rip3 in response to FFC diets (21), consistent with the lack of  protection from high-fat diets observed in 
Rip3–/– mice (16–18). In addition, this Rip3–/–-independent role of  MLKL in FFC diet-induced liver injury 
was associated with impaired autophagic flux (21).
Based on the available studies delineating the differential contributions of  RIP1-/RIP3-MLKL signal-
ing pathway in murine models of  ALD and NAFL/NASH, here we investigated the role of  Mlkl in etha-
nol-induced liver injury compared with its role in response to high-fat diet–induced liver injury. In contrast 
to the protection of  Mlkl–/– from liver injury in response to FFC diet (21); Mlkl-deficient mice were not pro-
tected from either chronic ethanol or acute on chronic (Gao-binge) ethanol-induced liver injury. Although 
the Gao-binge–induced expression of  inflammatory cytokines in the liver was decreased in Mlkl–/– mice, 
Mlkl-deficiency did not protect from Cxcl family chemokine expression and neutrophil accumulation, ste-
atosis, ER stress, or hepatocellular injury. Importantly, immunoreactive phospho-MLKL (pMLKL) was 
higher in livers of  patients with NASH compared with patients with AH or healthy controls (HCs), and 
circulating concentrations of  RIP1 and RIP3 distinguished patients with AH from NASH or HCs. Taken 
together, these data highlight that the molecular machinery in the RIP3-MLKL signaling network differ-
entially contribute to murine models of  AH and NAFL/NASH and that RIP1 and RIP3 might be useful 
biomarkers to distinguish AH from NASH.
Results
Differential expression and phosphorylation MLKL in livers of  patients with AH and NASH compared with HCs. RIP3 
expression is low in healthy livers (4); however, expression is increased in livers of  patients with ALD (8) and 
NAFL/NASH (14, 17). Although Afonso et al. (14) found somewhat elevated RIP3 in AH patients compared 
with NASH via immunohistochemistry, no data are available on direct comparisons of  MLKL expression 
between patients with different etiologies of  liver disease. We therefore evaluated the phosphorylation of  
MLKL in livers from patients with AH and NASH compared with HCs by Western blot (Figure 1, A and B) 
and immunohistochemistry (Figure 1C). Clinical and demographic data are provided in Table 1.
Liver homogenates from patients with AH and HCs were semiquantified on the same Western blot. 
The relative quantity of  MLKL and pMLKL were higher in AH compared with controls (Figure 1A). Next, 
a subset of  these HCs and patients with AH were directly compared on a single Western blot to patients 
with NASH (Figure 1B). As in Figure 1A, pMLKL was higher in patients with AH compared with HCs, 
pMLKL was higher in NASH compared with both AH and HCs (Figure 1B). In contrast, the relative total 
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Figure 1. MLKL and pMLKL expression in liver in patients with alcohol-associated hepatitis and nonalcoholic steatohepatitis. (A and B) Western blot 
analysis of MLKL and pMLKL expression in liver lysates from healthy controls (HCs) and patients with alcohol-associated hepatitis  (AH) (n = 5) (A) or HCs 
and patients with nonalcoholic steatohepatitis (NASH) and AH (n = 4–5) in liver lysates (B). HepG2 transfected with siRNA targeting MLKL were used 
as negative controls. (C) Paraffin-embedded human liver samples were deparaffinized followed by pMLKL immunostaining using standard immunohis-
tochemistry technique. Nuclei were counterstained with hematoxylin. For a negative control, a liver sample from a patient with NASH was processed 
without primary antibody. Arrowheads show typical pMLKL-positive area. pMLKL-positive areas were quantified using Image Pro-Plus software, excluding 
any tissues edges from the quantification. Images are representative on HC (n = 10), NAFL/NASH (n = 16), and AH (n = 10). Scale bar: 100 μm. P less than 
0.05, assessed by 2-way ANOVA; values with different alphabetical superscripts were significantly different from each other.
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MLKL expression was lower in NASH compared with AH and HCs. HepG2 cells transfected with siRNA 
targeted to MLKL were used as negative controls for detection of  MLKL (Figure 1A). Consistent with the 
Western blot data, pMLKL, assessed by immunohistochemistry, was higher in NASH and AH compared 
with HCs and also higher in NASH compared with AH (Figure 1C). Interestingly, the distribution of  
pMLKL across the parenchyma was also different between AH and NASH. In NASH, pMLKL-positive 
cells showed relatively uniform staining in the cytoplasm, whereas in AH, pMLKL-positive cells exhibited 
a more punctate staining pattern (Figure 1C). Taken together, these data suggest differential regulation of  
MLKL in livers from patients with AH and NASH.
Differential expression and distribution of  MLKL in liver of  ethanol-fed versus FFC diet-fed mice. If  MLKL, 
like RIP3, plays a differential role in ethanol-induced compared with FFC diet-induced liver injury in 
mice, then activation of  MLKL would be expected to differ between these 2 disease models. To test this 
hypothesis, MLKL expression in liver was compared between mice challenged with the Gao-binge model 
of  ethanol exposure and mice fed a FFC diet (Figure 2A). FFC diet, but not the Gao-binge ethanol proto-
col, increased immunoreactive MLKL expression (Figure 2A). Activation of  MLKL involves phosphory-
lation, oligomerization, and translocation to the PM (22). pMLKL expression, assessed by immunohisto-
chemistry, was also increased in response to the FFC diet, but not Gao-binge or chronic ethanol exposure 
(Figure 2B). We recently reported that feeding FFC diet induced the oligomerization and translocation of  
MLKL to the plasma membrane fraction in mouse liver (21). In contrast, here we found that MLKL did 
not oligomerize or translocate to the PM in response to Gao-binge ethanol exposure (Figure 2C). The lack 
of  translocation was particularly evident when compared directly to the impact of  FFC diet to increase 
MLKL oligomers in the PM fraction (Figure 2D).
Mlkl deficiency does not protect mice from indicators of  Gao-binge–ethanol- or chronic ethanol-induced liver injury. 
The low level of  pMLKL in AH compared with NASH in both murine models and patients’ livers sug-
gested that MLKL might not make a significant contribution to ethanol-induced liver injury. To evaluate 
the role of  MLKL in murine models of  ALD, Mlkl–/– mice and their littermate controls (Mlkl+/+) were 
exposed to the Gao-binge or a chronic model of  ethanol feeding. There were no major differences in body 
weights or food intake between genotypes (Supplemental Table 1; supplemental material available online 
with this article; https://doi.org/10.1172/jci.insight.140180DS1). Gao-binge ethanol exposure increased 
ALT, AST, and hepatic triglycerides in both female (Figure 3A) and male (Figure 3B) compared with 
pair-fed controls independently of  Mlkl genotype. Similarly, chronic ethanol feeding increased hepatic tri-
glycerides, ALT, and AST in both Mlkl+/+ and Mlkl–/– mice (Figure 3C). Moreover, H&E staining of  liver 
sections revealed a similar pattern of  macrovesicular and microvesicular steatosis in males and females of  








Age (yrs) 45.6 ± 6.7 52.4 ± 4.7 40.8 ± 3.5
Gender (male, %) 3 (60.0) 1 (25.0) 3 (60.0)
Decompensation (n, %) N/A 0 (0) 5 (100.0)
BMI (kg/m2) N/A 38.3 ± 2.9 N/A
Sepsis (n, %) N/A 0 (0) 0 (0)
Maddrey’s discriminant function N/A N/A 102.5 ± 27.7
Total bilirubin (mg/dL) N/A 0.6 ± 0.1 25.2 ± 5.1
AST (IU/L) N/A 72.3 ± 26.7 N/A
ALT (IU/L) N/A 93.3 ± 23.7 N/A
Prothrombin time (sec) N/A N/A 32.4 ± 5.7
NAS N/A 5.0 ± 0.4 N/A
Fibrosis score N/A 3.0 ± 0.0 N/A
Liver samples from HC and patients with AH were from Clinical Resource for Alcoholic Hepatitis Investigations 
at Johns Hopkins University and liver samples from patients with NASH were collected during S. Dasarathy’s 
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both genotypes in response to Gao-binge ethanol (Figure 3D). Histological scoring of  the H&E-stained 
liver sections was consistent with the biochemical assessment of  liver injury (Supplemental Table 2).
Gao-binge–induced ER stress and hepatocyte apoptosis were independent of  Mlkl genotype. Gao-binge–induced 
liver injury is also associated with increased CYP2E1 expression, ER stress, and hepatocyte apoptosis. 
CYP2E1 induction by Gao-binge was independent of  Mlkl genotype (Figure 4A). Similarly, phosphory-
lation of  EIF2A and induction of  CHOP, 2 indicators of  ER stress were increased in both Mlkl–/– mice 
and Mlkl+/+ (Figure 4B). Finally, accumulation of  M30, a specific marker of  caspase-dependent hepatocyte 
apoptosis, was increased by Gao-binge independently of  genotype (Figure 4C). Collectively, these data using 
Mlkl–/– mice indicate that Mlkl does not make a significant contribution to ethanol-induced liver injury.
Role of  Mlkl in inflammatory cytokine and chemokine expression and neutrophil infiltration in response to Gao-
binge ethanol exposure. Increased inflammatory cytokine expression has long been appreciated as an import-
ant contributor to ethanol-induced liver injury, owing, at least in part, to increased concentrations of  LPS 
in the portal circulation, resulting from impaired gut barrier function in response to ethanol (23). More 
recently, it has become evident that dysregulated chemokine expression is also a key feature of  ethanol-in-
duced liver injury, particularly related to the infiltration of  neutrophils (24–26). Gao-binge ethanol feeding 
increased Tnfa, Il1b and Mcp1 expression in liver of  Mlkl+/+, but not Mlkl–/–, mice (Figure 5A). In contrast, 
expression of  the chemokines Cxcl1 and Cxcl2 was increased in response to Gao-binge independent of  
genotype (Figure 5A). Consistent with the sustained increase in Cxcl1/Cxcl2, neutrophil accumulation in 
response to Gao-binge ethanol was also independent of  Mlkl genotype (Figure 5B).
Although immune cells in the liver are typically considered the primary source of  inflammatory cyto-
kines and chemokines, there is growing evidence that hepatocytes themselves are key sources of  chemokines 
(27, 28). By isolating primary hepatocytes from nonparenchymal cells of  livers of  control mice, MLKL was 
expressed in both cell populations (Supplemental Figure 1). Therefore, we hypothesized that Mlkl might dif-
ferentially contribute to cytokine and chemokine expression in hepatocytes compared with immune cells. 
Exposure of  AML12 hepatocytes to low concentrations of  LPS, similar to those observed in patients with 
AH or mice exposed to chronic ethanol, increased the expression of  Cxcl1 and Cxcl2 expression. This response 
was maintained even when Mlkl was knocked down using targeted siRNAs (Figure 5C). In contrast, when 
BM–derived macrophages from WT and Mlkl–/– mice were challenged with LPS, Tnfa, Il1b, and Mcp1 mRNA 
expression was lower in cells from Mlkl-deficient mice compared with WT (Figure 5D). Taken together, these 
data suggest that Mlkl-independent expression of  chemokines by hepatocytes, as well as neutrophil accumula-
tion, sustains Gao-binge–induced injury, despite a lowering of  some inflammatory cytokines.
Plasma concentrations of  RIP1, RIP3, and MLKL in patients with AH compared with NASH and HCs. Previous 
reports suggest that circulating concentrations immunoreactive RIP1, RIP3, and MLKL, assessed by com-
mercially validated ELISA kits, are associated with increased inflammation in lung injury (29) and sepsis 
(30). Although the cellular origin of  circulating RIP1, RIP3, and MLKL is unknown, circulating biomarkers 
can still provide useful diagnostic indicators. Therefore, we measured RIP1, RIP3, and MLKL concentrations 
in plasma from HCs, patients with AH, stratified by disease severity based on the model for end-stage liver 
disease (MELD) score (mild AH [MELD < 11], moderate AH [11 ≤ MELD < 20], severe AH [20 ≤ MELD 
< 26], very severe AH [MELD ≥ 26]) and patients with NASH. The clinical characteristics of  this cohort are 
shown in Table 2. Importantly, circulating concentrations of  RIP1 and RIP3 were dependent on the etiology 
of  liver disease in this cohort. RIP1 was lower in all AH patients independent of  severity compared with both 
HCs and patients with NASH (Figure 6A). RIP3 was also higher in AH compared with HCs and NASH and 
increased with severity of  AH (Figure 6A). In contrast, plasma MLKL concentration was not as responsive to 
Figure 2. Differential expression and activation of hepatic MLKL in mice exposed to Gao-binge ethanol diet compared with FFC diet. For a model of 
NAFL/NASH Mlkl+/+ mice were allowed free access to a Western diet high in fat, fructose, and cholesterol (FFC) for 12 weeks or standard chow diets. For a 
model of ALD, mice were allowed free access to the Lieber-DeCarli ethanol diet or pair-fed control diet for 10 days followed by an acute gavage of ethanol or 
maltose, respectively. (A) Western blot analysis of MLKL was measured in livers from mice fed the FFC diet or Gao-binge ethanol model. A liver sample from 
an Mlkl–/– mouse fed the FFC diet was used as a negative control. n = 4–10 per group. (B) Paraffin-embedded liver samples were deparaffinized and stained 
for pMLKL. Nuclei were counterstained with hematoxylin. Arrowheads show phospho-MLKL (pMLKL)-positive areas. An Mlkl–/– mouse exposed to the high-
fat diet feeding protocol was used as a negative control. Representative images are shown. n = 4–11 per group. Scale bar: 100 μm. P less than 0.05, assessed 
2-tailed t test (A) and 2-way ANOVA (B); values with different alphabetical superscripts were significantly different from each other. (C and D) Oligomeri-
zation and subcellular localization of MLKL in the livers of mice were assessed in the cytosol, 10,000g pellets (P10) and isolated plasma membranes (PMs). 
Proteins were resolved by nonreducing PAGE and probed with antibody to MLKL. A longer exposure is shown in the right panel to better illustrate MLKL 
in the PM fraction. (C) Distribution of MLKL monomer and oligomer in liver of mice exposed to Gao-binge ethanol. (D) Distribution of MLKL monomer and 
oligomer in liver of mice exposed to Gao-binge ethanol compared with FFC diet. Representative images are shown. C, chow; E, Gao-binge; F, FFC; P, pair-fed.
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Figure 3. Mlkl–/– mice are not protected from Gao-binge– or chronic ethanol-induced liver injury. (A–C) Female (A) and male (B) MLKL-deficient mice 
(Mlkl–/–) and their littermate controls (Mlkl+/+) were exposed to the Gao-binge ethanol diet as described in Figure 2 and chronic ethanol (C) as described in 
Supplemental Material. ALT and AST activities were measured in plasma, and triglyceride concentrations measured in liver. For females, n = 8–12 (A) and 
males, n = 4–6 (B) and female, n = 4–6 (C). P less than 0.05, assessed by 2-way ANOVA; values with different alphabetical superscripts were significantly 
different from each other. (D) H&E staining of livers in Gao-binge ethanol diet. Scale bar: 100 μm. Images are representative on n = 4–6 mice per group.
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disease severity or etiology (Figure 6A). RIP1 and RIP3, but not MLKL, were found to be good biomarkers 
for distinguishing AH from NASH (Figure 6B and Supplemental Table 3). To better compare the predictive 
value of  RIP1 and RIP3 to distinguish AH from NASH, independent of  disease severity, we also compared 
mild AH (MELD < 11) and NASH. Notably, subjects with similar MELD scores, RIP1, and RIP3 were still 
valuable in distinguishing AH from NASH (Figure 6C and Supplemental Table 3).
Recent data from Gautheron and colleagues found that the concentration of  RIP1 and MLKL 
increased in patients with NASH dependent on disease severity (9), but this study only evaluated circulat-
ing RIP1 and MLKL in patients with different severities of  NASH, without inclusion of  HCs (9). They 
found that RIP 1 and MLKL concentrations were higher in patients with more severe NASH (activity score 
≥ 2) compared with patients with milder NASH (activity score < 2) (9). We also analyzed RIP1, RIP3, 
Figure 4. Differential role of Mlkl on Gao-binge–induced increases in ER stress and hepatocyte apoptosis. (A and B) Expression of CYP2E1 (A) and ER 
stress markers (B) were assessed by Western blot analysis and normalized to HSC70 or GAPDH. (C) M30-positive hepatocytes (total number of cells per 
10X frame) were counted in formalin-fixed paraffin-embedded sections of liver. Arrowheads show typical M30-positive hepatocytes. Nuclei were counter-
stained with hematoxylin. Scale bar: 100 μm. n = 4–6 per group. P less than 0.05, assessed by 2-way ANOVA; values with different alphabetical super-
scripts were significantly different from each other.
9
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and MLKL concentration according to NAFLD activity score (NAS) in patients with NASH (n = 30, 1 
patient in our cohort did not have a recorded NAS), and found MLKL, but not RIP1 or RIP3, was higher 
in patients with NAS greater than or equal to 3 than those with NAS less than 3 (Supplemental Figure 2). 
Our cohort had only 2 patients with NAS less than 2, so, although there was a trend toward an increase, we 
could not statistically compare groups using NAS 2 as the cutoff  value. Taken together, these data suggest 
that there are increases in circulating MLKL in patients with NASH as severity of  disease increases, but the 
concentrations, even in more severe NASH, tend to be lower in patients with NASH compared with AH.
Plasma concentrations of  RIP1, RIP3, and MLKL and 90-day mortality in patients with AH. Since RIP1 and 
RIP3 were useful biomarkers to distinguish AH from NASH, we evaluated their ability to predict 90-day 
Figure 5. Differential role of Mlkl on Gao-binge–induced increases in inflammatory mediators and neutrophil accumulation. Female MLKL-deficient mice 
(Mlkl–/–) and their littermate controls (Mlkl+/+) were exposed to the Gao-binge ethanol diet as described in Figure 2. (A) mRNA expression for proinflamma-
tory cytokines and chemokines was detected in livers from using quantitative real-time PCR (qRT-PCR) and normalized to 18S rRNA. (B) NIMP-R14-positive 
cells (total number of cells per 10X frame) were counted in formalin-fixed paraffin-embedded sections of liver. Nuclei were counterstained with hematoxylin. 
Scale bar: 100 μm. (C) Chemokine expression in AML12 transfected with scrambled siRNA (NCR) or siRNA targeting Mlkl. Cells were challenged with 10 ng/
mL LPS for 1.5 hours and chemokine expression assessed by qRT-PCR. (D) Proinflammatory cytokine and chemokine expression in BM-derived macro-
phages (BMDMs) from Mlkl-deficient mice and WT controls. BMDMs were challenged with or without 10 ng/mL LPS for 24 hours and cytokine/chemokine 
expression assess by qRT-PCR. n = 4–6 per group for (A–C) and n = 4 for (D). P less than 0.05, assessed by 2-way ANOVA; values with different alphabetical 
superscripts were significantly different from each other.
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mortality in patients with AH who had survival data (n = 106). RIP3, but not RIP1 or MLKL, was differ-
ent between patients who survived compared with those who died before 90 days (Figure 7A). In addition, 
RIP3 concentrations could better predict 90 days mortality in AH compared with RIP1 and MLKL (Figure 
7B and Supplemental Table 3). By using the value 16,305 pg/mL as a cutoff  value in RIP3, we found that 
patients with RIP3 concentrations above this cutoff  had poorer prognoses after their diagnosis (Figure 7C), 
suggesting RIP3 may be a promising biomarker to predict prognosis in AH after diagnosis.
Discussion
Multiple pathways of  regulated cell death are implicated in the progression of  metabolic liver diseases; 
however, the contributions of  individual pathways of  regulated cell death to specific liver diseases are not 
well understood (31). Studies using Rip3–/– mice find that the contributions of  RIP3 to liver injury vary con-
siderably depending on the insult (4, 5, 7). Although RIP3 contributes to ethanol-induced liver injury (8, 
11), as well as MCD-diet fed mice (14, 17), several studies using high-fat diet–induced models of  NAFL/
NASH find that Rip3 does not contribute to liver injury (16, 18, 32). Although the role of  RIP3 has been 
studied in multiple models of  liver injury (4, 5, 7), much less is known about the role of  MLKL, the down-
stream effector of  necroptotic cell death, in liver disease. Recent studies revealed that Mlkl–/– mice are pro-
tected from liver injury induced by an FFC diet (21), as well as high-fat diet–induced insulin resistance (20). 
Although no gold standard exists for assessing necroptosis, the clear involvement of  Mlkl in murine models 
of  NAFL/NASH implicates necroptotic cell death in disease development. If  the contributions of  RIP3 to 
Table 2. Demographic and clinical data from healthy controls and patients with NASH, mild AH, moderate AH, and severe AH (samples 
used for ELISA)
AH (n = 245)




MELD < 11 
(n = 25)
Moderate AH 
11 ≤ MELD < 20 
(n = 83)
Severe AH 
20 ≤ MELD < 26 
(n = 76)
Very severe AH 
26 ≤ MELD 
(n = 61)
P value
Age (yrs) 53.4 ± 1.9A,B 54.7 ± 1.9A 49.5 ± 1.8A,B 48.9 ± 1.2A,B 47.3 ± 1.2B 48.7 ± 1.2A,B 0.007
Gender (N, %)       0.009
Male 10 (45.4) 11 (35.5) 14 (56.0) 52 (62.7) 48 (63.2) 45 (73.8)
Female 12 (54.5) 20 (64.5) 11 (44.0) 31 (37.4) 28 (36.8) 16 (26.2)
Race (N, %)       0.407
White 21 (95.5) 29 (93.6) 22 (88.0) 77 (92.8) 69 (90.8) 56 (91.8)
Black 0 (0) 0 (0) 2 (8.0) 5 (6.0) 6 (7.9) 4 (6.6)
Asian 1 (4.5) 1 (3.2) 0 (0) 0 (0) 0 (0) 0 (0)
Hispanic 0 (0) 1 (3.2) 0 (0) 0 (0) 0 (0) 0 (0)
OthersE 0 (0) 0 (0) 1 (4.0) 1 (1.2) 1 (1.3) 1 (1.6)
Blood test       
Albumin (g/dL) 4.3 ± 0.1A 4.6 ± 0.1A 3.7 ± 0.1B 2.9 ± 0.1C 2.6 ± 0.1D 2.7 ± 0.1C,D <0.0001
Bilirubin (mg/dL) 0.7 ± 1.4A 0.6 ± 1.2A 1.1 ± 1.2A 6.0 ± 0.7B 14.3 ± 0.7C 24.1 ± 0.8D <0.0001
AST (IU/L) 21.4 ± 1.7A 50.9 ± 8.0A 66.0 ± 9.6A 116.9 ± 8.9B 132.6 ± 8.7B 122.6 ± 7.4B <0.0001
ALT (IU/L) 20.0 ± 2.1A 65.8 ± 14.9B 32.7 ± 3.6A,C 48.8 ± 3.9B,C 48.9 ± 4.3B,C 52.7 ± 3.9B,C 0.001
INR 1.0 ± 0.0A 1.1 ± 0.0A 1.1 ± 0.0A 1.4 ± 0.0B 1.8 ± 0.0C 2.1 ± 0.1D <0.0001
Creatinine (mg/dL) 1.0 ± 0.1 1.1 ± 0.1 0.8 ± 0.2 0.7 ± 0.1 0.8 ± 0.1 1.9 ± 0.1B <0.0001
Liver function       
Child-Pugh score N/A 5.3 ± 0.3A 6.1 ± 0.3A 8.6 ± 0.2B 10.4 ± 0.1C 11.1 ± 0.2D <0.0001
MELD score N/A 9.5 ± 1.1A 8.2 ± 0.3A 15.8 ± 0.3B 22.9 ± 0.2C 30.8 ± 0.7D <0.0001
Pathological findings       
Inflammation score N/A 3.8 ± 0.3 N/A N/A N/A N/A
Samples from HC and patients with NASH were obtained from the Northern Ohio Alcohol Center biorepository (NCT03224949), and samples from patients 
with AH were recruited from the Liver Unit of the Hospital Clínic Barcelona and 4 medical centers participating in the Defeat Alcoholic Steatohepatitis 
(DASH) consortium (Cleveland Clinic, University of Louisville School of Medicine, University of Massachusetts Medical School, and University of Texas 
Southwestern Medical Center). A,B,C,DValues with different alphabetical superscripts were significantly different from each other. EThe information about 
race of these patients is unavailable. P less than 0.05, assessed by 2-way ANOVA. AH, alcohol-associated hepatitis; ALT, alanine transaminase; AST, 
aspartate transaminase; HC, healthy controls; MELD, model for end-stage liver disease; NASH, nonalcoholic steatohepatitis; PT, prothrombin time.
1 1
R E S E A R C H  A R T I C L E
JCI Insight 2021;6(4):e140180  https://doi.org/10.1172/jci.insight.140180
ethanol-induced liver injury were due to activation of  necroptosis, we would expect that Mlkl–/– mice would 
be protected from injury. However, here we find that, in contrast to high-fat diet-induced obesity, Mlkl defi-
ciency does not protect mice from ethanol-induced liver injury. Even in Mlkl-deficient mice, acute chronic 
ethanol exposure induced ER stress and hepatocellular injury, associated with increased Cxcl1 and Cxcl2 
chemokine expression and neutrophil infiltration.
Additionally, we provide evidence that the concentration of circulating components of the necroptotic 
signaling network, RIP1 and RIP3, may provide important insight into the development of biomarkers to dis-
tinguish AH from NASH. Such biomarkers are becoming increasingly important as many patients presenting 
with symptoms of metabolic liver disease are both obese and chronic heavy drinkers (33). In our study, the 
circulating concentrations of RIP1 and RIP3 were different in patients with AH compared with NASH, even 
when AH patients were stratified by disease severity. Majdi and colleagues (9) reported that concentrations of  
RIP1 and MLKL were increased in serum of patients with NASH in patients with activity score greater than 
or equal to 2 compared with those with activity score less than 2. When we stratified our NASH cohort by 
disease severity (Supplemental Figure 2), our data were partially consistent with this report, in that the concen-
tration of MLKL, but not RIP1 or RIP3, was higher in patients with NAS greater than or equal to 3 compared 
with those with NAS less than 3. Taken together, these data indicate that circulating MLKL is increased with 
NASH severity. Importantly, in our cohort of patients with AH and NASH, the RIP1 and RIP3 concentrations 
were still different between AH and NASH, even when stratified for disease severity based on MELD scores. 
Our data are consistent with previous work using circulating biomarkers of apoptosis in NAFL/NASH and 
AH. Feldstein and colleagues (34) originally developed CK18 as a biomarker for NAFL. CK18 is a cyto-
keratin exclusively expressed in hepatocytes within the liver. Release of full-length CK18 (M65) is indicative 
of necrotic/necroptotic cell death, whereas release of the caspase-dependent cleavage product M30 indicates 
Figure 6. Quantity of RIP1, RIP3, and MLKL in plasma from HCs and patients with AH and NASH. (A) ELISA assays for RIP1, RIP3, and MLKL were con-
ducted in plasma from HCs (n = 22) and patients diagnosed with NASH (n = 31), mild AH (MELD < 11, n = 25), moderate AH (11 ≤ MELD < 20, n = 83), severe 
AH (20 ≤ MELD < 26, n = 76), or very severe AH (MELD ≥ 26, n = 61). P < 0.05, assessed by 2-way ANOVA; values with different alphabetical superscripts 
were significantly different from each other. (B) Receiver operating characteristic (ROC) curves show the predictive values of RIP1, RIP3, and MLKL to dis-
tinguish all AH from NASH. (C) ROC curves show the predictive values of RIP1, RIP3, and MLKL to distinguish mild AH (MELD < 11) from NASH.
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caspase-dependent apoptosis of hepatocytes. In NAFL, the caspase-dependent cleavage product M30 predom-
inates in the circulation (34), whereas in AH, M65 is predominant (35).
In murine models of  metabolic liver disease, the expression, phosphorylation, and intracellular local-
ization of  MLKL was differentially regulated in response to Gao-binge ethanol compared with FFC diets. 
Although hepatic MLKL expression was relatively low in control mice, it was increased in response to FFC 
diets, but not Gao-binge. Increased expression in response to FFC diets, but not Gao-binge, was associat-
ed with increased phosphorylation of  MLKL, oligomerization, and translocation to the PM. In FFC diets, 
accumulation of  MLKL in liver is associated with impaired autophagic flux (21). Gao-binge ethanol also 
impairs autophagic flux, in a mechanism dependent on TFEB expression (36). However, our data suggest 
that impaired autophagic flux in the context of  Gao-binge ethanol exposure is insufficient to result in the 
accumulation of  MLKL in the liver. It is possible that impaired autophagic flux is more predominant in FFC 
diets and/or that there are additional stimuli involved in the induction of  MLKL in response to high-fat diets.
When previous studies using global Rip3–/– mice observed protection of  liver injury in response to a vari-
ety of  insults, including ethanol-induced liver injury (8, 11), acetaminophen-induced injury (12, 13), MCD 
diets (14), and concanavalin-A induced hepatitis (15), it was assumed that this protection was associated 
with a prevention of  cell death receptor–mediated necroptotic cell death. However, RIP3 has a number of  
noncanonical functions that are independent of  necroptosis, including activation of  the inflammasome (37, 
38). These functions are likely to be particularly important in the context of  ethanol-induced liver injury 
in which the inflammasome is known to contribute to injury (39). Because MLKL is the ultimate down-
stream effector of  necroptotic cell death, only protection from injury in the absence of  MLKL can be a true 
indicator for a pathophysiological role of  necroptosis in disease progression. Importantly, here we find that 
Mlkl–/– are not completely protected from Gao-binge– or chronic ethanol-induced liver injury, suggesting that 
necroptosis is not an important driver of  hepatocellular injury in this model of  ethanol-induced liver injury.
Figure 7. Association between the plasma concentrations of RIP1, RIP3, and MLKL and prognosis in patients with AH. (A) RIP3, not RIP1 and MLKL, can 
predict 90-day mortality in AH (survival n = 83, death n = 23). Values with different alphabetical superscripts were significantly different from each other. P 
less than 0.05, assessed by 2 tailed t test. (B) ROC curves show the predictive values of RIP1, RIP3, and MLKL to predict 90 days mortality in patients with 
AH. (C) The patients with high concentration of RIP3 (n = 64) have poor prognosis compared with those at a low concentration of RIP3 (n = 42) (log-rank P < 
0.001). The best cutoff value was based on the calculation of Youden index, which takes into account the sensitivity and the specificity.
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However, it is notable that Mlkl-deficient mice were protected from some of  the Gao-binge– induced 
increases in expression of  some inflammatory mediators, including Tnfa, Il1b, and Mcp1, but not other chemo-
kines, such as Cxcl1 and Cxcl2. In the liver, both hepatocytes and immune cells contribute to increased inflam-
matory responses (40, 41). Hepatocytes are not typically considered to be important contributors to inflam-
mation in the liver. However, hepatocytes respond to stress by activating multiple drivers of  inflammation 
(42–44). For example, hepatocytes produce MCP1 and macrophage migration inhibitory factor, 2 important 
chemokines that contribute to ethanol-induced liver injury in murine models, in response to ethanol (45–47). 
Interestingly, using cultured monocytic cells, Kearney et al. reported that MLKL-dependent necroptotic cell 
death could limit inflammatory mediator production (48, 49). Further, Kang et al. (50) showed the IL1B 
production was suppressed by knockdown of MLKL in LPS-treated DCs. In contrast, Yoon and colleagues 
(51) found that Mlkl deficiency in HT29 colon cells did not impair TNF-stimulated chemokine production. 
Here, we also report that LPS-stimulated expression of  Cxcl1 and Cxcl2, important chemokines stimulating 
neutrophil recruitment (27), was also independent of  Mlkl in AML12 hepatocytes. The sustained expression 
of  Cxcl1/2 was consistent with the Mlkl-independent accumulation of  neutrophils in livers of  Gao-binge etha-
nol–exposed mice. Taken together, these data suggest that there are likely cell-specific mechanisms of  MLKL 
action in the liver in response to Gao-binge ethanol. This hypothesis will require studies using cell-specific 
deletions of  Mlkl to distinguish the role of  MLKL in hepatocytes versus immune cells.
Understanding the complex contributions of RIP1-RIP3 and MLKL in human disease is important, as 
necroptotic cell death has been associated with more than 30 human diseases (52), including cancer (53) and 
more than 20 approved drugs have the potential to regulate necroptosis (52). Taken together, our data in murine 
models and patients with AH and NASH suggest that circulating markers of specific cell death pathways would 
be potential biomarkers of the etiology of metabolic liver diseases. These data indicate that, given the difficulty 
of collecting biopsy samples in NASH and AH patients, development of RIP1, RIP3, and MLKL as a panel 
of less-invasive circulating biomarkers for NASH and AH may address an important unmet clinical need (54).
Methods
Human liver and plasma samples. For Western blots and immunohistochemistry, samples from 5 livers explant-
ed from patients with severe AH during liver transplantation and 5 wedge biopsies from healthy donor livers 
were snap frozen in liquid nitrogen and stored at –80°C. AH and healthy donor samples were provided by 
the NIAAA R24 Clinical Resource for Alcoholic Hepatitis Investigations at Johns Hopkins University. Sam-
ples from patients with NASH were obtained from 2 sources: wedge biopsies collected from 4 patients with 
NASH were provided by S. Dasarathy (NCT00323414) for Western blot analysis, and the liver sections used for 
immunohistochemistry from 16 patients with NAFL/NASH were obtained from the Cleveland Clinic Surgical 
Pathology CoPath database with the assistance of the Northern Ohio Alcohol Center. Descriptive demograph-
ic and clinical data from the patients used for Western blots are provided in Table 1.
For RIP1, RIP3, and MLKL ELISA assays, plasma from a total of 298 subjects was included in this study. 
Deidentified plasma samples, along with clinical and demographic data, were obtained from 22 healthy individ-
uals and 31 patients with NASH from the Northern Ohio Alcohol Center biorepository (NCT03224949). For-
ty-four patients with AH were recruited from the Liver Unit of the Hospital Clínic Barcelona, between January 
2000 and September 2007, and 201 patients with AH from 4 medical centers participating in the Defeat Alcohol-
ic Steatohepatitis (DASH) consortium (Cleveland Clinic, University of Louisville School of Medicine, Univer-
sity of Massachusetts Medical School, and University of Texas Southwestern Medical Center) (55). Of the AH 
cohort from DASH consortium, 107 AH patients were followed for 180 days. Detailed descriptions of patient 
recruitment, inclusion and exclusion criteria for the Barcelona AH cohort (28), and DASH AH cohort (55) have 
been reported in previous studies. Patients with AH were stratified as mild AH (MELD < 11, n = 25), moderate 
AH (11 ≤ MELD < 20, n = 83), severe AH (20 ≤ MELD < 26, n = 76), and very severe AH (MELD ≥ 26, n = 
61). Descriptive demographic and clinical data are provided in Table 2. This study was approved by the IRBs of  
all participating institutions, and all study participants consented prior to collection of data and blood samples.
Animals and feeding trials. All animals received humane care. Mlkl−/− mice were purchased from Taconic 
Biosciences (TF2780) and were backcrossed with C57BL/6J from The Jackson Laboratory (Bar Harbor, 
ME, USA) until congenic. C57BL/6J background was confirmed in the Mlkl−/− and Mlkl+/+ using the SNP 
Genome Scan service at The Jackson Laboratory. For the ethanol feeding models, 8- to 10-week-old male 
and female mice were allowed free access to the Lieber-DeCarli high-fat ethanol diet or pair-fed control diets. 
Two ethanol feeding models, a chronic feeding model and the Gao-binge model, were used in this study. For 
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the high-fat diet feeding studies, 5-week-old male mice were allowed free access to a diet high in FFC for 12 
weeks as a model of  high-fat diet–induced obesity; controls were fed standard chow diets. Additional details 
of  the feeding protocols and tissue collection can be found in Supplemental Materials and Methods.
Subcellular fractionation and PM isolation in murine liver. PM fractions were isolated using the PM pro-
tein extraction kit (ab65400, Abcam). Liver tissues were washed twice with ice-cold PBS, resuspended in 
homogenization buffer and lysed using a Dounce homogenizer (50 strokes). Homogenates were centri-
fuged to obtain the cytosolic fraction as well as the 10,000g pellet. The pellet was further purified according 
to the manufacturer’s instructions to obtain purified PM proteins.
Biochemical assays, histopathology, immunohistochemistry, Western blot, and ELISAs. Detailed methods can 
be found in the Supplemental Materials and Methods; the lists of  the primers for quantitative PCR (qPCR) 
and antibodies for WB are also available in the Supplemental Table 4 and 5.
Statistics. Values shown in all figures represent the means ± SEM. Values with different alphabetical super-
scripts were significantly different from each other. Statistical analysis was performed using SAS statistical 
software (SAS Institute) and STATA, version 16.0 (IBM). Data were log-transformed as necessary to obtain a 
normal distribution. Group comparisons were made by unpaired 2-tailed t test or 2-way ANOVA in continuous 
variables and by χ2 test or Fisher’s exact test where appropriate in categorical variables. ANOVA was performed 
using the general linear models procedure and follow-up comparisons made by least-squares means testing. 
The diagnostic accuracy for the diagnosis of AH, NASH, and prognostic accuracy of 90-day mortality of  
AH patients was evaluated using receiver operating characteristic curves. The leave-one-out cross-validation 
method was used to assess predictive potential and to limit model overfitting. The best cutoff  values were based 
on the calculation of Youden index, which takes into account the sensitivity and the specificity. Kaplan-Meier 
survival curves were plotted to estimate the cumulative probability of mortality for RIP3 related to 90-day 
mortality in patients with AH from DASH consortium. A P value of less than 0.05 was considered significant.
Study approval. For human samples, written informed consent was obtained from all patients and all 
samples were deidentified. These studies were approved by the Institutional Review Boards at Johns Hop-
kins Medical Institutions, the Cleveland Clinic, MetroHealth Hospitals, or the Ethics Committee of  the 
Hospital Clinic of  Barcelona. Studies included in the DASH consortium were approved by the Institutional 
Review Boards at University of  Massachusetts, University of  Louisville, Cleveland Clinic, and University 
of  Texas Southwest. All procedures using animals were approved by the Cleveland Clinic IACUC.
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